Article,
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Contributors
Monge S.
0000-0003-1412-3012
(Corresponding author)
[1]
[2]
Braeye T.
0000-0002-5637-4613
Hansen C.H.
0000-0002-5949-0097
[5]
Emborg H.-D.
0000-0001-8062-0864
[5]
Castilla J.
0000-0002-6396-7265
[7]
[8]
de Gier B.
0000-0002-9067-090X
[9]
Kristoffersen A.B.
0000-0003-2313-9622
[10]
Soares P.
0000-0001-5033-9115
[11]
Nardone A.
0000-0003-1138-0937
[3]
Kissling E.
0000-0001-7188-8404
[3]
Affiliations
- [1] CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III [NORA names: Spain; Europe, EU; OECD];
- [2] Instituto de Salud Carlos III [NORA names: Spain; Europe, EU; OECD];
- [3] Epiconcept [NORA names: France; Europe, EU; OECD];
- [4] European Centre for Disease Prevention and Control [NORA names: Sweden; Europe, EU; Nordic; OECD];
- [5] Statens Serum Institut [NORA names: SSI Statens Serum Institut; Governmental Institutions; Denmark; Europe, EU; Nordic; OECD];
(... more)
Abstract
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65- to 79-year-olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
